Learning Objectives

Overall Learning Objectives:

  • Articulate the new CCS Guidelines recommendations for treatment of HFrEF
  • Understand how important comorbid conditions impact management of heart failure
  • Describe the new stepwise approach to the diagnosis of HFpEF
  • Be aware of new and emerging heart failure treatments
  • Understand the practical intersection between the environment and the failing heart
  • Develop an approach to incorporate virtual heart failure care


New HF Guidelines for a New Era

Michael McDonald, MD

  1. Review the highlights from the 2021 heart failure guidelines
  2. Incorporate new drugs for patients with acute or chronic heart failure
  3. Discuss options for medication titration in HFrEF

Treating HFrEF: What Comes After the Big Four?

Nadia Giannetti, MD

  1. Discuss if we should further optimize patients who have a ‘special’ presentation
  2. Discuss treatment options beyond the ‘big 4’
  3. Review new studies that were presented in the last year

In-Hospital HF Management

Lisa Mielniczuk, MD

  1. Discuss the approach to the ADHF patients
  2. Provide suggested approaches for transition from intravenous to oral therapy
  3. Discuss the roles of inotropes and venodilators

Something in the Air: Environmental Effects Upon the Failing Heart

Deepak Bhatt, MD

  1. Explain how poor air quality may worsen heart failure
  2. Describe strategies to avoid negative impacts of pollution in everyday life
  3. List ways in which COVID-19 may impact HF patients


JACC HF: Great HF Papers of the Past Year

Christopher O’Connor, MD

  1. Review the most impactful JACC-HF papers of 2020/2021 and understand how they impact your practice

Control of Atrial Rate and Rhythm in 2021

Jason Andrade, MD

  1. Describe the role of rate and rhythm control for atrial fibrillation in patients with heart failure
  2. Understand the role of ablation procedures in heart failure

Current and Future Role of Artificial Intelligence in Diagnosis of HF

Carolyn Lam, MD

  1. 'Democratize' the use of diagnostic testing, e.g. ECHO with AI support
  2. Identify (case findings) of HF in large datasets using AI
  3. Predict repeat hospitalization and death in cohorts of HF patients

Special Imaging for Special Cardiomyopathies

Robert Beanlands, MD

  1. Describe the role for Nuclear imaging (PET and SPECT) in the diagnosis of cardiac sarcoid and amyloidosis
  2. Describe the advantages of Cardiac MRI in defining specific types of cardiomyopathy (highlights from the OUTSMART trial)
  3. Discuss a few potential pitfalls of advanced cardiac imaging 


Five Things to Know About Diagnosis of HFpEF

Gianluigi Savarese, MD 

  1. Describe the HFA algorithm for diagnosis of heart failure
  2. Describe the role of 'special testing' for establishing a heart failure diagnosis
  3. Understand when and where the diagnostic algorithm should be used with caution

Five Things to Know About Treatment of HFpEF

Scott Solomon, MD

  1. Describe the heterogeneity of heart failure phenotypes and HFmrEF
  2. Understand newer medications and their role in HFpEF and HFmrEF
  3. Describe non-medicine approaches for treatment of HFpEF

Is it Prime Time for IV Iron?

Eileen O’Meara, MD

  1. Understand key abnormalities of iron metabolism in patients with heart failure
  2. Describe current status of treatment for iron deficiency in acute and chronic heart failure
  3. Describe ongoing clinical trials examining the role of IV iron therapy for people with heart failure

Emerging Alternatives for Decongesting HF

Petar Seferovic, MD

  1. Discuss the current role of implantable hemodynamic monitoring in chronic heart failure
  2. Describe current data for newer devices for treatment of heart failure including carotid sinus stimulators, atrial shunts, splanchnic nerve blockade


Treatment of the Diuretic Resistant Patient with Acute HF

Stephanie Poon, MD

  1. Understand the contributors to diuretic resistance in patients with volume overload
  2. Describe a stepped approach to diuretic management in the resistant patient
  3. Describe potential alternatives to traditional diuretic treatment for volume overload

Dyspnea NYD: Pulmonary or Cardiac and What to do Next

Michael Heffernan, MD

  1. Appreciate the differential diagnosis of a patient presenting with dyspnea
  2. Describe an approach to distinguish heart failure from other causes of dyspnea
  3. Understand the benefits and limitations of BNP as an adjunct to the clinical assessment

Which Elderly Patients Can Be Considered for Inotropic Therapy?

Dr. Phyllis Billia, MD 

  1. Discuss the role of inotropes in advanced heart failure and cardiogenic shock
  2. Identify outcomes of elderly patients supported with inotropes
  3. Provide a rationale for palliative inotrope therapy

Should We Integrate New HF Drugs During In-Hospital Care?

Anil Gupta, MD 

  1. Discuss the existing data supporting in-hospital initiation of new heart failure drugs
  2. Review the upcoming clinical trials that will further explore in hospital initiation 
  3. Review the downstream benefits of in-hospital initiation


Next Door Neighbor: The Liver in HF 


  1. Distinguish the features of a congested versus an under perfused liver
  2. Understand common cardiac manifestations of severe liver disease
  3. Describe an approach to assessment and treatment of heart failure in the setting of cirrhosis

Cardiodiabetes in 2021

Subodh Verma, MD

  1. Understand key pathophysiologic links between diabetes and heart function
  2. Describe modern treatment of heart failure in persons with diabetes
  3. Describe how treatments for diabetes may impact concomitant heart failure

Percutaneous Treatment of AV Valve Regurgitation

Neil Fam, MD

  1. Provide an update on role of Mitra Clip in persons with heart failure
  2. Describe early results of tricuspid valve interventions
  3. Discuss the role of the heart failure practitioner in percutaneous valve programs

Cancer as a Precursor to HF

Ronald Wittles, MD

  1. Describe the risk of development of heart failure following treatments of many cancers
  2. Develop a rational cardiac surveillance of patients receiving typical cancer therapeutic agents
  3. Describe strategies to ameliorate or prevent key cardiac complications of oncologic medications

WORKSHOPS: Friday Afternoon

POCUS in HF: Back by Popular Demand

Ryan Davey, MD
Sharon Mulvagh, MD

  1. Understand the purpose and basic components of point of care ultrasound (POCUS)     
  2. Describe typical POCUS findings associated with heart failure
  3. Understand the pitfalls of POCUS technology and interpretation

Guide to Drug Withdrawal in HFrecEF

Abhinav Sharma, MD 

  1. Understand which patients with HFrEF are most likely to recover LV function
  2. Review the data showing the risk of therapy withdrawal in patients with recovered LVEF
  3. Describe clinical scenarios of patients who have recovered LV function

Identifying Frailty in HF and Why it Matters

Jonathan Afilalo, MD

  1. Become familiar with practical tools to assess frailty
  2. Understand the relationship between frailty and adverse health outcomes
  3. Determine how to de-frail patients to optimize outcomes

Optimizing HF and Device Therapy After Cardiac Device Implantation

Kiran Sidhu, MD

  1. Interpret CRT diagnostics and recognize opportunities for optimization
  2. Discuss clinical pathways for optimization of GDMT
  3. Review successful integrated HF programs for optimization in device clinics

WORKSHOPS: Saturday Morning

A Shared Decision-Making Approach to Goals of Care

Caroline McGuinty, MD

  1. Describe a framework for incorporation of palliative care within the treatment team
  2. Discuss how to determine best timing for periodic goals of care discussion
  3. Describe how palliative care can improve the heart team performance

Practical Approach to HF Medication

Rodolfo Pike, NP
Nadia Thomson, NP

  1. Understand practical tips to initiating and up-titrating Quadruple therapy
  2. Review tools for counselling patients on safety considerations of therapies
  3. Compare and contrast novel approaches to prescribing Quadruple therapy

Virtual HF Monitoring

Patrice Lindsay, RN, PhD (Heart & Stroke)
Mary O'Sullivan, RN

  1. Evaluate the appropriate application of virtual care for HF monitoring and management
  2. Assess different models of virtual care
  3. Describe emerging tools to assist in delivery of virtual care

L’échocardiographie chez l’insuffisant cardiaque: paramètres au-delà de la FEVG

Catherine Bourque, MD

  1. Identifier les marqueurs pronostiques échocardiographiques de l'insuffisance cardiaque 
  2. Intégrer les informations échocardiographiques pour guider le traitement de l'insuffisance cardiaque 
  3. Expliquer les nouvelles avancées échocardiographiques dans l'évaluation de la fonction ventriculaire  

WORKSHOPS: Saturday Afternoon

Effects of Non-CV Drugs on the Heart

Ricky Turgeon, PharmD

  1. Describe non-cardiovascular drugs that can cause or exacerbate heart failure, and summarize the best-available evidence
  2. Recognize common, serious, and emerging interactions with heart failure drugs, and summarize the best-available evidence
  3. Consider treatment alternatives to mitigate drug safety issues in patients with heart failure

How to Involve QA in Hospital HF Care

Robert McKelvie, MD

  1. Describe how to determine local quality of your care indicators
  2. Describe key heart failure performance indicators that matter
  3. Identify items you can implement in your clinic

CCS/CHFS Heart Failure Guidelines - Evidence to Support Innovation in Practice 

Sean Virani, MD

  1. Discuss new evidence for pharmacological therapies in patients with heart failure and reduced ejection fraction (HFrEF) 
  2. Discuss the timing and clinical context for initiating newer pharmacologic therapies for management of HFrEF 
  3. Apply practical strategies to integrate the Canadian Cardiovascular Society/Canadian Heart Failure Society heart failure guidelines into daily clinical practice  

Lignes directrices de la SCC et de la SCIC sur l’insuffisance cardiaque- Preuves soutenant l’innovation dans la pratique 

Eileen O’Meara, MD

  1. Discussion sur les nouvelles preuves pour les thérapies pharmacologiques des patients atteints d’insuffisance cardiaque avec fraction d’éjection réduite (ICFER)
  2. Discussion sur le moment opportun et le contexte clinique propices à entreprendre de nouvelles thérapies pharmacologiques pour la prise en charge de l’ICFER
  3. Mise en œuvre de stratégies pratiques d’intégration des Lignes directrices sur l’insuffisance cardiaque de la Société canadienne de cardiologie et de la Société canadienne d’insuffisance cardiaque à la pratique clinique de tous les jours

What Has ISCHEMIA Taught us About Coronary Revascularization for HFrEF

Robert Miller, MD

  1. Describe the rationale for viability testing in patients with HF 
  2. Understand the pitfalls of non-invasive assessments of ischemia in patients with cardiomyopathy 
  3. Develop your own framework for assessment of suitability for coronary revascularization in the setting of heart failure


Follow @CanHFSociety Along on Twitter